Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients M. SandströmH. LindmanM.O. Karlsson Original Article 08 February 2006 Pages: 143 - 156
A phase 1 and pharmacokinetic study of gemcitabine and oxaliplatin in patients with solid tumors Hui K. GanPaul L. MitchellMatthew Links Original Article 19 November 2005 Pages: 157 - 164
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors Henry C. PitotAlex A. AdjeiCharles Erlichman Original Article 19 November 2005 Pages: 165 - 172
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors Yasuhide YamadaTomohide TamuraYutaka Natsumeda Original Article 25 November 2005 Pages: 173 - 182
Potassium oxonate, an enzyme inhibitor compounded in S-1, reduces the suppression of antitumor immunity induced by 5-fluorouracil Tetsuro YamashitaYuji UedaHisakazu Yamagishi Original Article 30 November 2005 Pages: 183 - 188
Phase-I study of a new schedule based on increasing days of topotecan administration associated with dose individualisation Jean-Pierre DelordFrédéric LégerEtienne Chatelut Original Article 22 November 2005 Pages: 189 - 194
Antiproliferative and Antiproteolytic activity of Pentoxifylline in cultures of B16F10 Melanoma cells Pooja DuaRajiv P. Gude Original Article 06 December 2005 Pages: 195 - 202
Second-line chemotherapy with weekly paclitaxel and gemcitabine in patients with small-cell lung cancer pretreated with platinum and etoposide: a single institution phase II trial Vincenzo DongiovanniLucio BuffoniOscar Bertetto Original Article 06 December 2005 Pages: 203 - 209
Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro Cindy SimoensJan B. VermorkenFilip Lardon Original Article 30 November 2005 Pages: 210 - 218
The radiosensitising effect of difluorodeoxyuridine, a metabolite of gemcitabine, in vitro Bea PauwelsAnnelies E. C. KorstJan B. Vermorken Original Article 06 December 2005 Pages: 219 - 228
Folate receptor specific anti-tumor activity of folate–mitomycin conjugates Joseph A. ReddyElaine WestrickChristopher P. Leamon Original Article 06 December 2005 Pages: 229 - 236
Gemcitabine aerosol: in vitro antitumor activity and deposition imaging for preclinical safety assessment in baboons Frédéric GagnadouxValérie LeblondEtienne Lemarié Original Article 19 November 2005 Pages: 237 - 244
Preferential extravasation and accumulation of liposomal vincristine in tumor comparing to normal tissue enhances antitumor activity Siqing ShanClay FlowersMark W. Dewhirst Original Article 08 December 2005 Pages: 245 - 255
Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells Britta K. StordalMary W. DaveyRoss A. Davey Original Article 10 November 2005 Pages: 256 - 265
Biweekly regimen of cisplatin, gemcitabine and vinorelbine for advanced non-small-cell lung cancer Javier Castro de CarpeñoM. González BarónThe Oncopaz Cooperative Group (Spain) Original Article 25 November 2005 Pages: 266 - 271
Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency Joseph CiccoliniCedric MercierBruno Lacarelle Short Communication 15 November 2005 Pages: 272 - 275
5-Fluorouracil can cross brain–blood barrier and cause encephalopathy: should we expect the same from capecitabine? A case report on capecitabine-induced central neurotoxicity progressing to coma V. FormicaA. LearyY. J. Chua Short Communication 07 December 2005 Pages: 276 - 278
Molecular targets of cancer chemotherapy K. S. ZaenkerG. MustacchiE. Mihich Meeting Report 24 December 2005 Pages: 279 - 282
Angiotensin 1–7 and risk for breast cancer recurrence Kadri AltundagOzden AltundagSelahattin Turen Letter to the editor 22 November 2005 Pages: 283 - 283
Reply to letter to the editors (K Altundag et al.) Gere S. diZeregaKathleen E. Rodgers Letter to the editor 06 December 2005 Pages: 284 - 284